Clinical Trials

Showing trials with last updates posted in 2024.

NCT03691376 | TERMINATED | PHASE1
4 participants

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Study Type:
INTERVENTIONAL
Last Updated:
2024-09-19
Start Date:
2019-03-08
Completion:
2021-01-30
Conditions
  • Platinum-Resistant Fallopian Tube Carcinoma
  • Platinum-Resistant Ovarian Carcinoma
  • Platinum-Resistant Primary Peritoneal Carcinoma
  • Platinum-Sensitive Fallopian Tube Carcinoma
  • Platinum-Sensitive Ovarian Carcinoma
  • Platinum-Sensitive Primary Peritoneal Carcinoma
  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Ovarian Carcinoma
  • Recurrent Primary Peritoneal Carcinoma
  • Refractory Fallopian Tube Carcinoma
  • Refractory Ovarian Carcinoma
  • Refractory Primary Peritoneal Carcinoma
Interventions
  • BIOLOGICAL
  • OTHER
  • DRUG
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page